Related Experiment Video

Updated: Apr 27, 2026

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
06:43

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

27.2K

Brain hypothermia therapy for status epilepticus in childhood

G Imataka1, K Wake, H Yamanouchi

  • 1Department of Pediatrics; Dokkyo Medical University School of Medicine, Tochigi, Japan. geo@dokkyomed.ac.jp.

European Review for Medical and Pharmacological Sciences
|July 11, 2014
PubMed

Insights

Dokkyo Medical University Hospital implemented a brain hypothermia protocol for childhood seizures and encephalitis. This therapy aims to reduce brain temperature to 34-35°C for 48 hours to manage neurological complications.

Area of Science:

  • Pediatric Neurology
  • Critical Care Medicine
  • Neuroscience

Background:

  • Status epilepticus and acute encephalitis/encephalopathy pose significant neurological risks in children.
  • Early intervention is crucial for improving outcomes in severe pediatric neurological conditions.

Purpose of the Study:

  • To review the brain hypothermia therapy protocol introduced at Dokkyo Medical University Hospital.
  • To outline the application and management of therapeutic hypothermia for pediatric neurological emergencies.

Main Methods:

  • Protocol applies to infants ≥6 months or 7.5 kg with prolonged seizures (≥30 min) or specific conditions like hypoxic-ischemic encephalopathy.
  • Therapeutic hypothermia involves cooling to 34.0-35.0°C within 6 hours, maintained for 48 hours in the ICU.
  • Concomitant treatments include steroid pulse therapy, sedation with sodium thiopental, and controlled rewarming.

Main Results:

  • The protocol details the target temperature range (34.0-35.0°C) and duration (48 hours) for hypothermia.
  • Specific methods for induction, maintenance, and rewarming are described, including adjunct therapies.
  • The review focuses on the procedural aspects of implementing brain hypothermia therapy.

Conclusions:

  • This paper provides a comprehensive review of the established brain hypothermia therapy protocol.
  • The protocol serves as a guide for managing severe pediatric neurological conditions requiring therapeutic hypothermia.
Abstract

More Related Videos

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms05:00

Short-Duration Hypothermia Induction in Rats using Models for Studies examining Clinical Relevance and Mechanisms

Published on: March 3, 2021

4.4K
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

33.8K

Related Concept Videos

Methods of reducing fever01:22

Methods of reducing fever

The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
1.6K
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
1.2K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Increased Body Temperature01:25

Increased Body Temperature

A body temperature above  38°C  (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...
6.4K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K